These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

205 related items for PubMed ID: 12761249

  • 1. Plasminogen activator inhibitor-1 is a significant determinant of renal injury in experimental crescentic glomerulonephritis.
    Kitching AR, Kong YZ, Huang XR, Davenport P, Edgtton KL, Carmeliet P, Holdsworth SR, Tipping PG.
    J Am Soc Nephrol; 2003 Jun; 14(6):1487-95. PubMed ID: 12761249
    [Abstract] [Full Text] [Related]

  • 2. Endogenous alpha2-antiplasmin does not enhance glomerular fibrin deposition or injury in glomerulonephritis.
    Kitching AR, Turner AL, O'Sullivan KM, Dewerchin M, Lijnen HR.
    J Thromb Haemost; 2003 Sep; 1(9):1992-9. PubMed ID: 12941042
    [Abstract] [Full Text] [Related]

  • 3. Glomerular fibrinolytic activity in anti-GBM glomerulonephritis in rabbits.
    Malliaros J, Holdsworth SR, Wojta J, Erlich J, Tipping PG.
    Kidney Int; 1993 Sep; 44(3):557-64. PubMed ID: 8231028
    [Abstract] [Full Text] [Related]

  • 4. Deficiency of growth factor midkine exacerbates necrotizing glomerular injuries in progressive glomerulonephritis.
    Kojima H, Kosugi T, Sato W, Sato Y, Maeda K, Kato N, Kato K, Inaba S, Ishimoto T, Tsuboi N, Matsuo S, Maruyama S, Yuzawa Y, Kadomatsu K.
    Am J Pathol; 2013 Feb; 182(2):410-9. PubMed ID: 23201132
    [Abstract] [Full Text] [Related]

  • 5. Type 1 plasminogen activator inhibitor deficiency aggravates the course of experimental glomerulonephritis through overactivation of transforming growth factor beta.
    Hertig A, Berrou J, Allory Y, Breton L, Commo F, Costa De Beauregard MA, Carmeliet P, Rondeau E.
    FASEB J; 2003 Oct; 17(13):1904-6. PubMed ID: 12897066
    [Abstract] [Full Text] [Related]

  • 6. mRNA expression of urokinase and plasminogen activator inhibitor-1 in human crescentic glomerulonephritis.
    Lee HS, Park SY, Moon KC, Hong HK, Song CY, Hong SY.
    Histopathology; 2001 Aug; 39(2):203-9. PubMed ID: 11493338
    [Abstract] [Full Text] [Related]

  • 7. Protease-activated receptor-2 augments experimental crescentic glomerulonephritis.
    Moussa L, Apostolopoulos J, Davenport P, Tchongue J, Tipping PG.
    Am J Pathol; 2007 Sep; 171(3):800-8. PubMed ID: 17640968
    [Abstract] [Full Text] [Related]

  • 8. Tissue factor, plasminogen activator inhibitor-1, and thrombin receptor expression in human crescentic glomerulonephritis.
    Grandaliano G, Gesualdo L, Ranieri E, Monno R, Schena FP.
    Am J Kidney Dis; 2000 Apr; 35(4):726-38. PubMed ID: 10739796
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. TGF-beta type II receptor deficiency prevents renal injury via decrease in ERK activity in crescentic glomerulonephritis.
    Song CY, Kim BC, Hong HK, Lee HS.
    Kidney Int; 2007 May; 71(9):882-8. PubMed ID: 17299519
    [Abstract] [Full Text] [Related]

  • 11. Plasminogen and plasminogen activators protect against renal injury in crescentic glomerulonephritis.
    Kitching AR, Holdsworth SR, Ploplis VA, Plow EF, Collen D, Carmeliet P, Tipping PG.
    J Exp Med; 1997 Mar 03; 185(5):963-8. PubMed ID: 9120402
    [Abstract] [Full Text] [Related]

  • 12. Tissue factor initiates glomerular fibrin deposition and promotes major histocompatibility complex class II expression in crescentic glomerulonephritis.
    Erlich JH, Holdsworth SR, Tipping PG.
    Am J Pathol; 1997 Mar 03; 150(3):873-80. PubMed ID: 9060825
    [Abstract] [Full Text] [Related]

  • 13. Dysfunction of glomerular fibrinolysis in experimental antiglomerular basement membrane antibody glomerulonephritis.
    Feng L, Tang WW, Loskutoff DJ, Wilson CB.
    J Am Soc Nephrol; 1993 May 03; 3(11):1753-64. PubMed ID: 8329670
    [Abstract] [Full Text] [Related]

  • 14. A mutant, noninhibitory plasminogen activator inhibitor type 1 decreases matrix accumulation in experimental glomerulonephritis.
    Huang Y, Haraguchi M, Lawrence DA, Border WA, Yu L, Noble NA.
    J Clin Invest; 2003 Aug 03; 112(3):379-88. PubMed ID: 12897205
    [Abstract] [Full Text] [Related]

  • 15. Vitronectin dictates intraglomerular fibrinolysis in immune-mediated glomerulonephritis.
    Mesnard L, Rafat C, Vandermeersch S, Hertig A, Cathelin D, Xu-Dubois YC, Jouanneau C, Keller AC, Ribeil JA, Leite-de-Moraes MC, Rondeau E.
    FASEB J; 2011 Oct 03; 25(10):3543-53. PubMed ID: 21764994
    [Abstract] [Full Text] [Related]

  • 16. Expression of glomerular plasminogen activator inhibitor type 1 in glomerulonephritis.
    Hamano K, Iwano M, Akai Y, Sato H, Kubo A, Nishitani Y, Uyama H, Yoshida Y, Miyazaki M, Shiiki H, Kohno S, Dohi K.
    Am J Kidney Dis; 2002 Apr 03; 39(4):695-705. PubMed ID: 11920334
    [Abstract] [Full Text] [Related]

  • 17. Crescentic glomerulonephritis is diminished in fibrinogen-deficient mice.
    Drew AF, Tucker HL, Liu H, Witte DP, Degen JL, Tipping PG.
    Am J Physiol Renal Physiol; 2001 Dec 03; 281(6):F1157-63. PubMed ID: 11704568
    [Abstract] [Full Text] [Related]

  • 18. Tissue factor pathway inhibitor expression in human crescentic glomerulonephritis.
    Cunningham MA, Ono T, Hewitson TD, Tipping PG, Becker GJ, Holdsworth SR.
    Kidney Int; 1999 Apr 03; 55(4):1311-8. PubMed ID: 10200995
    [Abstract] [Full Text] [Related]

  • 19. Sequential studies of glomerular crescent formation in rats with antiglomerular basement membrane-induced glomerulonephritis and the role of coagulation factors.
    Silva FG, Hoyer JR, Pirani CL.
    Lab Invest; 1984 Oct 03; 51(4):404-15. PubMed ID: 6434880
    [Abstract] [Full Text] [Related]

  • 20. Intrinsic renal cells are the major source of tumor necrosis factor contributing to renal injury in murine crescentic glomerulonephritis.
    Timoshanko JR, Sedgwick JD, Holdsworth SR, Tipping PG.
    J Am Soc Nephrol; 2003 Jul 03; 14(7):1785-93. PubMed ID: 12819238
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.